SLC25A48 expression in COPD patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, prospective observational study will measure SLC25A48 expression in peripheral blood mononuclear cells from people with COPD or pre-COPD and compare it to healthy controls. Researchers will examine how SLC25A48 levels correlate with inflammatory markers, choline metabolites, and routine clinical data such as pulmonary function and nutrition status. The study uses Western blot and image-based analysis to quantify transporter expression, alongside standard blood tests and quality-of-life assessments. Participants will undergo pulmonary function testing and nutritional evaluation to explore associations with disease-related inflammation and metabolism. No intervention is applied; the study aims to identify potential biomarker links and inform future research on mitochondrial choline transport in COPD.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* pre-COPD or COPD stages I-IV as per the 2023 GOLD guidelines (case group)
* healthy individuals without chronic diseases or major medical conditions

Exclusion Criteria:

* diagnosed with neuromuscular diseases
* experienced respiratory disease exacerbation requiring emergency care or hospitalization in the past three months
* assessed by a physician to have severe malnutrition or a significantly low BMI
* continuously taking folic acid supplements
* willing to receive or have already received self-paid nutrition clinic services at this hospital

Where it's running

• Fu Jen Catholic University Hospital, Fu Jen Catholic University
  New Taipei City, Taiwan Recruiting
• Cardinal Tien Hospital
  New Taipei City, Taiwan Not yet recruiting

Study contacts

• Principal investigator: Ke-Yun Chao, PhD — Fu Jen Catholic University
• Study coordinator: Ke-Yun Chao, PhD
• Email: ck_qq@hotmail.com
• Phone: +886-905-301-879

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Flutter therapy added to chest physiotherapy after CABG in COPD patients

  This study tests whether adding Flutter therapy to standard chest physiotherapy helps post-CABG patients with mild-to-moderate COPD improve breathing more than chest physiotherapy alone.

  Recruiting Foundation University Islamabad · Rawalpindi · NCT07875049

• TPB-based cadence exercise and breathing training for COPD patients

  A TPB-based program tests whether breathing training, cadence-guided walking, or both can improve lung function, exercise capacity, and quality of life in adults with COPD.

  Recruiting Fu Jen Catholic University Hospital · New Taipei City, New Taipei City and 1 other locations · NCT07860008

• See how dynamic chest X-rays relate to COPD patterns and progression risk

  This study looks at existing dynamic chest radiography data to see if new imaging measurements can identify COPD patterns, gauge severity, and predict who may experience faster progression.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07762573

• Personalized mobile app warnings to reduce COPD flares

  A personalized mobile app tests whether providing temperature-related risk warnings and protective tips, in addition to usual COPD care, can lower COPD flare-ups over 12 months.

  Recruiting at 4 sites Centers for Disease Control and Prevention, China · Beijing and 3 other locations · NCT07656142

• CLEAR model to predict when people with severe COPD can be taken off ventilatory support

  This project will see if the CLEAR model can predict which adults with severe COPD on invasive or non‑invasive ventilation can be safely taken off ventilatory support.

  Recruiting Assiut University · Asyut, Assuit Egypt · NCT07579052

• Long-term safety of Tozorakimab in COPD patients with prior exacerbations

  This study tests two long-term dosing regimens of tozorakimab in people with COPD who have a history of flare-ups and who completed earlier studies.

  Recruiting at 5 sites Phase 3 AstraZeneca · Aix-en-Provence and 12 other locations · NCT07566195

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.